Skip to main content

Advertisement

Table 2 In vitro antimicrobial activity of the synthesized compounds

From: Design, synthesis and biological evaluation of 3-(2-aminooxazol-5-yl)-2H-chromen-2-one derivatives

Comp. Antimicrobial screening (MIC = µM)
SA EC BS PA SE CA AN
1 61.5 61.5 61.5 30.8 61.5 30.8 30.8
2 72.2 72.2 72.2 36.1 36.1 36.1 72.2
3 14.8 14.8 59.2 59.2 59.2 29.6 29.6
4 63.5 63.5 31.7 63.5 63.5 31.7 31.7
5 59.2 59.2 59.2 29.6 59.2 29.6 29.6
6 71.3 71.3 71.3 35.6 17.8 35.6 17.8
7 34.6 34.6 34.6 69.2 69.2 34.6 34.6
8 34.9 34.9 17.5 69.8 69.8 34.9 69.8
9 77.6 77.6 38.8 38.8 77.6 38.8 38.8
10 36.5 36.5 73.0 36.5 73.0 36.5 36.5
11 69.2 34.6 34.6 34.6 69.2 69.2 69.2
12 34.6 34.6 34.6 34.6 69.2 34.6 69.2
13 63.5 63.5 63.5 31.7 63.5 31.7 63.5
14 69.1 69.1 69.1 17.3 69.1 34.5 69.1
15 65.1 65.1 32.6 32.6 65.1 32.6 65.1
Cefadroxil 17.2 17.2 17.2 17.2 17.2
Fluconazole 20.4 20.4
  1. SA, Staphylococcus aureus, EC, Escherichia coli; BS, Bacillus subtilis; PA, Pseudomonas aeruginosa; SE, Salmonella enterica; CA, Candida albicans; AN, Aspergillus niger